Celltrion Progresses COVID-19 Antibody Therapeutic, Pricing Will Be Key
Executive Summary
Celltrion presses ahead with Phase I study of COVID-19 antibody therapeutic, encouraged by the support of the South Korean government. The firm also urges global cooperation to lower prices of COVID-19 drugs and vaccines to end the global pandemic.
You may also be interested in...
Korea Seeks Two-Track Strategy For COVID-19 Drugs, Vaccines
As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.
Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral
Moderna maintains its lightning pace, but questions about its Phase III trial design remain.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.